HBV Epidemiology & Mortality
Hepatitis B and C Reduce Survival by More than 20 Years
- Details
- Category: HBV Epidemiology & Mortality
- Published on Monday, 23 December 2013 00:00
- Written by Liz Highleyman
People with chronic hepatitis B or C lived about 2 decades less on average than those who did not have these infections, and chronic viral hepatitis was the 15th leading cause of death in the U.S. in 2010, CDC researchers reported in the January 1, 2014, issue of Clinical Infectious Diseases.
AASLD 2013: Viral Hepatitis Epidemics in the U.S. and California
- Details
- Category: HBV Epidemiology & Mortality
- Published on Wednesday, 27 November 2013 00:00
- Written by Liz Highleyman
Deputy Assistant Secretary for Health Ronald Valdisseri described the hepatitis B and C epidemics in the U.S., the HCV cascade of care, and efforts to combat viral hepatitis at the AASLD Liver Meeting this month in Washington, DC. Public health officials in California also recently released a report on the hepatitis B and C epidemics in that state.
Chronic Hepatitis Cohort Study Sheds Light on Burden of Hepatitis B and C in U.S.
- Details
- Category: HBV Epidemiology & Mortality
- Published on Friday, 01 February 2013 00:00
- Written by Liz Highleyman
People born between 1945 and 1964 account for the highest proportion of hepatitis B and C cases, and these viruses are a significant cause of illness and death, according to an analysis described in the January 1, 2013, Clinical Infectious Diseases.
High Rate of New Hepatitis B Among African-Americans, Study Finds
- Details
- Category: HBV Epidemiology & Mortality
- Published on Wednesday, 11 September 2013 00:00
- Written by Liz Highleyman
Black Americans have a higher incidence of hepatitis B virus (HBV) infection than any other racial/ethnic group, including Asian-Americans, according to a review article in the July 1, 2013, advance edition of Clinical Gastroenterology and Hepatology.
ICAAC 2012: Switching to Tenofovir in ART Regimen Suppresses Hepatitis B in HIV/HBV Coinfected
- Details
- Category: HBV Epidemiology & Mortality
- Published on Friday, 14 September 2012 00:00
- Written by Liz Highleyman
HIV/HBV coinfected people who substituted tenofovir DF (Viread) for zidovudine (AZT; Retrovir) or abacavir (Ziagen) in their antiretroviral regimen saw a reduction in hepatitis B viral load, despite HBV resistance to lamivudine (3TC; Epivir), according to a poster presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) this week in San Francisco.
More Articles...
- ICAAC 2012: Hepatitis B Vaccine Effective Long-term, but Some Lose Protection after 15 Years
- Hepatitis B Rates Higher than Expected among Gay Men, Drug Users, Vaccinated Babies
- More than 2 Million People in U.S. May Have Chronic Hepatitis B
- Hepatitis C Deaths Now Outnumber Deaths from HIV; Screening Cost-Effective for Baby Boomers
Web Design and Development by